Based on Lund University research, group B streptococcus vaccine developer Minervax has now raised $11.4m from investors including Novo.

Minervax, a Denmark-based vaccine developer based on Lund University research, has raised €4.4m ($5m) in a round led by pharmaceutical firm Novo’s antimicrobial resistance-focused Repair Impact Fund.
Repair Impact Fund invested $4.1m through the deal, with the remaining $900,000 supplied by venture capital firm Sunstone Life Science Ventures.
Founded in 2010, Minervax is working on a vaccine for group B streptococcus (GBS), a normal bacterium that can cause life-threatening infections when present in newborn babies.
The vaccine…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?